Patents by Inventor Ursula MUELLER-VIEIRA

Ursula MUELLER-VIEIRA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted 3-phenoxyazetidin-1-yl-pyrazines
    Patent number: 11780827
    Abstract: The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: October 10, 2023
    Assignees: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Graeme Semple, Yifeng Xiong, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Scott Hobson, Uta Friederike Lessel, Frank Runge, Ursula Mueller-Vieira, Julian Wippich
  • 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament
    Patent number: 11691960
    Abstract: The present invention relates to novel 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamides of formula A and pharmaceutically acceptable salts thereof, wherein R1 to R3 are as defined herein. The invention also relates to processes for the preparation of these compound, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions in which inhibition of the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme may be beneficial.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: July 4, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stephan Georg Mueller, Kelly Allers, Klaus Klinder, Ursula Mueller-Vieira, Henning Priepke, Alexander Pautsch
  • 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT
    Publication number: 20230131465
    Abstract: The invention relates to 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) for use as a medicament, pharmaceutical compositions comprising at least a compound of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: September 9, 2022
    Publication date: April 27, 2023
    Applicants: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Daniela Gavina Berta, Marco Ferrara, Kirsten Gutsche, Ursula Mueller-Vieira, Scott Hobson, Frank Runge, Graeme Semple, Viktor Vintonyak, Yifeng Xiong
  • SUBSTITUTED 3-PHENOXYAZETIDIN-1-YL-PYRAZINES
    Publication number: 20220356172
    Abstract: The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: March 29, 2021
    Publication date: November 10, 2022
    Applicants: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Graeme Semple, Yifeng Xiong, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Scott Hobson, Uta Friederike Lessel, Frank Runge, Ursula Mueller-Vieira, Julian Wippich
  • 2-[Thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use therof as medicament
    Publication number: 20220144796
    Abstract: The present invention relates to novel 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamides of formula A and pharmaceutically acceptable salts thereof, wherein R1 to R3 are as defined herein. The invention also relates to processes for the preparation of these compound, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions in which inhibition of the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme may be beneficial.
    Type: Application
    Filed: November 4, 2021
    Publication date: May 12, 2022
    Inventors: Stephan Georg MUELLER, Kelly ALLERS, Klaus KLINDER, Ursula MUELLER-VIEIRA, Henning PRIEPKE, Alexander PAUTSCH
  • Selective inhibitors of human corticosteroid synthases
    Patent number: 9271963
    Abstract: The invention relates to compounds for selectively inhibiting human corticosteroid synthases CYP1 1 B1 and CYP1 1 B2, and to the production and use thereof for treating hypercortisolism, diabetes mellitus, hyperaldosteronism, cardiac insufficiency, myocardial fibrosis, depression, age-related cognitive decline and metabolic syndrome.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: March 1, 2016
    Assignee: UNIVERSITAT DES SAARLANDES
    Inventors: Rolf Hartmann, Marieke Voets, Ursula Müller-Vieira
  • Selective Inhibitors of Human Corticosteroid Synthases
    Publication number: 20090221591
    Abstract: The invention relates to compounds for selectively inhibiting human corticosteroid synthases CYP1 1 B1 and CYP1 1 B2, and to the production and use thereof for treating hypercortisolism, diabetes mellitus, hyperaldosteronism, cardiac insufficiency, myocardial fibrosis, depression, age-related cognitive decline and metabolic syndrome.
    Type: Application
    Filed: March 2, 2006
    Publication date: September 3, 2009
    Applicant: Universitat Des Saarlandes
    Inventors: Rolf W. Hartmann, Marieke Voets, Ursula Müller-Vieira